Clinical-stage biopharmaceutical company GH Research PLC (NASDAQ:GHRS) announced positive results from recent clinical trials of its leading 5-MeO-DMT formula, a therapy candidate for patients ...
A new neuroscience study reports that the psychedelic compound DMT disrupts a key brain rhythm linked to self-awareness.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results